- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2011-11-04 15:42:41
- Reporting Period:
- Filing Date:
- Filing Date Changed:
- Accepted Time:
- 2011-11-04 16:42:41
- Original Submission Date:
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1333248||Cadence Pharmaceuticals Inc||CADX||Pharmaceutical Preparations (2834)||000000000|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1244823||B James Breitmeyer||C/o Cadence Pharmaceuticals, Inc. |
12481 High Bluff Drive, Suite 200
San Diego CA 92130
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Sec. Name||Sec. Type||Acquisiton - Disposition||Date||Amount||Price||Amount - 2||Price - 2|
|Common Stock||Restricted Stock Units||Disposition||2011-11-02||12,500||$0.00||12,500||$0.00|
|Remaning Holdings||Exercise Date||Expiration Date||Equity Swap Involved||Transaction Form Type||Transaction Code||Nature of Ownership|
- Each restricted stock unit represented the right to receive one share of common stock on the earlier of (a) the one-year anniversary of FDA approval of the Company's NDA for intravenous acetaminophen, and (b) immediately prior to the consummation of a change in control of the Company, subject to the recipient's continued status as an employee, independent director or consultant of the Company or any subsidiary on the applicable vesting date. The Company received FDA approval of its NDA for intravenous acetaminophen on November 2, 2010.
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2011.
- This transaction was executed in multiple trades at prices ranging from a low of $5.65 to a high of $5.76. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).